儿童轻度糖尿病酮症酸中毒皮下门冬胰岛素治疗的成本效果估计
该经济学评价纳入2015年1月1日至2020年3月15日就诊于单家学术医疗中心急诊科、年龄2至14岁的轻度DKA患儿129例(平均年龄9.9岁,标准差3.1;女童72例,占55.8%),比较皮下门冬胰岛素(70例)与静脉常规胰岛素(59例)的成本效果。皮下胰岛素组住院时间较静脉组缩短(均值差16.9小时,95%CI -31.0至-2.9;P=0.005),住院费用更低(皮下组1071.99美元,标准差523.89;静脉组1648.90美元,标准差788.03;P=0.001),增量成本效果比为-34.08美元/小时(95%CI -25.97至-129.82)。控制年龄和性别后,皮下门冬胰岛素与较短的住院时间相关(β=-17.22,95%CI -32.41至-2.04;P=0.03)。作者认为,在儿童轻度无并发症DKA管理中,皮下门冬胰岛素相对于静脉常规胰岛素为优势方案。
要点
- 儿童轻度DKA中,皮下门冬胰岛素组住院费用1071.99美元(标准差523.89),低于静脉常规胰岛素组1648.90美元(标准差788.03),P=0.001。
- 皮下门冬胰岛素组住院时间较静脉组缩短(均值差16.9小时,95%CI -31.0至-2.9;P=0.005)。
- 增量成本效果比为-34.08美元/小时(95%CI -25.97至-129.82),皮下门冬胰岛素为优势方案。
- 控制年龄和性别后,皮下门冬胰岛素与较短的住院时间相关(β=-17.22,95%CI -32.41至-2.04;P=0.03)。
- 该研究为单中心经济学评价,纳入2至14岁轻度DKA患儿129例,其中皮下组70例、静脉组59例。
适用人群与场景
- 2015年1月1日至2020年3月15日就诊于单家学术医疗中心急诊科、年龄2至14岁的轻度DKA患儿。
- 共纳入129例轻度DKA发作患儿,其中女童72例(55.8%),平均年龄9.9岁(标准差3.1)。
处置流程与药物剂量
- 皮下门冬胰岛素:70例患儿接受皮下门冬胰岛素治疗。
- 静脉常规胰岛素:59例患儿接受静脉常规胰岛素输注。
研究设计与关键结果
- 研究类型:经济学评价,基于单家学术医疗中心急诊科2015年1月1日至2020年3月15日收治的129例轻度DKA患儿病历资料。
- 干预与对照:皮下门冬胰岛素(70例)vs 静脉常规胰岛素(59例)。
- 主要终点:增量成本效果比为-34.08美元/小时(95%CI -25.97至-129.82)。
- 住院时间:皮下胰岛素组较静脉组缩短均值16.9小时(95%CI -31.0至-2.9;P=0.005)。
- 住院费用:皮下胰岛素组1071.99美元(标准差523.89),低于静脉组1648.90美元(标准差788.03);P=0.001。
- 控制年龄和性别后,皮下门冬胰岛素与较短的住院时间相关(β=-17.22,95%CI -32.41至-2.04;P=0.03)。
证据类型、等级与局限
- 证据类型:基于临床数据的单中心经济学评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在儿童轻度无并发症DKA管理中,皮下门冬胰岛素相对于静脉常规胰岛素为优势方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Intravenous (IV) insulin infusion is the standard of care for treating diabetic ketoacidosis (DKA) worldwide. Subcutaneous (SC) insulin aspart could decrease the use of health care resources.
OBJECTIVE: To compare the cost-effectiveness of mild uncomplicated DKA management with SC insulin aspart vs IV insulin infusion among pediatric patients from the perspective of a public health care payer using clinical data.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation included children aged 2 to 14 years presenting to the emergency department of a single academic medical center with mild DKA between January 1, 2015, and March 15, 2020. The medical records for DKA treatment course and its associated hospitalization costs were reviewed. Data were analyzed from January 1, 2015, to March 15, 2020.
EXPOSURES: Subcutaneous insulin aspart vs IV regular insulin infusion.
MAIN OUTCOMES AND MEASURES: The incremental cost-effectiveness ratio (US dollars per hour), duration of DKA treatment, and length of hospital stay.
RESULTS: A total of 129 children with mild DKA episodes (mean [SD] age, 9.9 [3.1] years; 72 girls [55.8%]) were enrolled in the study. Seventy children received SC insulin aspart and 59 received IV regular insulin. Overall, the length of hospital stay in the SC insulin group was reduced (mean, 16.9 [95% CI, -31.0 to -2.9] hours) compared with the IV insulin group (P = .005). The mean (SD) cost of hospitalization in the SC insulin group (US $1071.99 [US $523.89]) was less than that in the IV insulin group (US $1648.90 [US $788.03]; P = .001). The incremental cost-effectiveness ratio was -34.08 (95% CI, -25.97 to -129.82) USD/h. The use of SC insulin aspart was associated with a lower likelihood of prolonged hospital stay (β = -17.22 [95% CI, -32.41 to -2.04]; P = .03) than IV regular insulin when controlling for age and sex.
CONCLUSION AND RELEVANCE: Findings of this economic evaluation suggest that SC insulin aspart is dominant vs IV regular insulin in the management of mild uncomplicated DKA in children.
参考来源
- Bali IA, Al-Jelaify MR, AlRuthia Y, et al. Estimated Cost-effectiveness of Subcutaneous Insulin Aspart in the Management of Mild Diabetic Ketoacidosis Among Children. JAMA Netw Open. 2022. PMID: 36066894. doi:10.1001/jamanetworkopen.2022.30043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。